Mannose-binding lectin (MBL) - deficient patients who undergo chemotherapy for a solid tumor might have an increased risk developing febrile neutropenia (FN). We investigated in a prospective cohort study relations between MBL-serum levels and polymorphisms in MBL promotor genotypes (550H/L and 221X/Y) on incidence and severity of FN. Risk of FN was 17.9% in MBL-deficient and 22.5% in MBL-sufficient patients (RR ¼ 0.796, p ¼ 0.45). Median MBL serum levels at baseline were respectively 1.39 mg/mL and 1.09 mg/mL (p ¼ 0.92) in patients with and without FN. In conclusion, serum MBL and MBL genotypes (550H/L and 221X/Y) do not determine the risk for developing FN.

Additional Metadata
Keywords Mannose-binding lectin (MBL), Solid tumors, Febrile neutropenia, MBLgenotype, MBL-deficiency
Persistent URL dx.doi.org/10.1080/07357907.2019.1582660, hdl.handle.net/1765/116827
Series VSNU Open Access deal
Journal Cancer Investigation
Note First author Goudzwaard affiliated with ErasmusMC
Citation
Epskamp, C., Goudzwaard, J.A, Fiets, E., Zuetenhorst, J.M., Polee, M.B, van de Geijn, G.J.M, … Hamberg, A.P. (2019). Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor. Cancer Investigation, 37(3), 156–162. doi:10.1080/07357907.2019.1582660